Buckingham Asset Management LLC Has $123,000 Stake in Galectin Therapeutics Inc. (GALT)
Buckingham Asset Management LLC maintained its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,000 shares of the company’s stock at the end of the second quarter. Buckingham Asset Management LLC owned about 0.14% of Galectin Therapeutics worth $123,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of GALT. US Bancorp DE boosted its position in shares of Galectin Therapeutics by 30.9% in the first quarter. US Bancorp DE now owns 118,921 shares of the company’s stock worth $274,000 after buying an additional 28,087 shares in the last quarter. KCG Holdings Inc. raised its stake in Galectin Therapeutics by 1.9% in the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after buying an additional 1,592 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. raised its stake in Galectin Therapeutics by 57.2% in the first quarter. Cutter & CO Brokerage Inc. now owns 56,600 shares of the company’s stock worth $130,000 after buying an additional 20,600 shares during the last quarter. 11.18% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) opened at 1.75 on Wednesday. Galectin Therapeutics Inc. has a 1-year low of $0.49 and a 1-year high of $3.68. The company’s market capitalization is $61.34 million. The company’s 50 day moving average price is $2.04 and its 200-day moving average price is $2.27.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same period last year, the company earned ($0.20) EPS. On average, equities analysts forecast that Galectin Therapeutics Inc. will post ($0.56) earnings per share for the current year.
GALT has been the topic of a number of analyst reports. ValuEngine lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Tuesday, May 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $2.25.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.